Investing Profile

Ali Behbahani

VCInvestor
General Partner at New Enterprise Associates (NEA)
nea.com/team/ali-behbahani-mdPhiladelphia, Pennsylvania
Photo of Ali Behbahani, General Partner at New Enterprise Associates (NEA)

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$2.0M - $50.0M
$25.0M
20
$6.2B
CompanyStageDateRound SizeTotal Raised
858 Therapeutics
Series BSep 2024$50M
Series ASep 2021$60M
$110M
Co-investors: Clare Ozawa (Versant Ventures)
Amber Therapeutics
Series AJun 2024$100M
$100M
Co-investors: Tiffany Le (New Enterprise Associates (NEA)), Kevin Chu (F-Prime Capital Partners), Caroline Gaynor (Lightstone Ventures)
Nexo Therapeutics
Series AJul 2023$60M
$60M
Co-investors: Carlo Rizzuto (Versant Ventures)
Launchpad Therapeutics
Series ADec 2022$30M
$30M
Co-investors: Alexander Mayweg (Versant Ventures)
Tune Therapeutics
Series ADec 2021$40M
$40M
Stablix
Series AJun 2021$63M
$63M
Co-investors: Carlo Rizzuto (Versant Ventures)
Monte Rosa Therapeutics
Series CMar 2021$95M
Series BSep 2020$96M
Series AMay 2020$33M
$220M
Co-investors: Alexander Mayweg (Versant Ventures), Markus Warmuth (Versant Ventures), Andrew Schiff (Aisling Capital)
Spyglass Ophthalmics
Series BJan 2021$28M
Series AMay 2019
$28M
Co-investors: Tak Cheung (New Enterprise Associates (NEA)), Cynthia Yee (Vensana Capital)